Abbott India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
Published on 09/11/2023 at 13:39
Share
Abbott India Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 14,941.4 million compared to INR 13,793.3 million a year ago. Revenue was INR 15,496.5 million compared to INR 14,130.1 million a year ago. Net income was INR 3,129.4 million compared to INR 2,655.2 million a year ago. Basic earnings per share from continuing operations was INR 147.27 compared to INR 124.95 a year ago.
For the six months, sales was INR 29,731.4 million compared to INR 26,834.6 million a year ago. Revenue was INR 30,846.5 million compared to INR 27,437.4 million a year ago. Net income was INR 6,031.8 million compared to INR 4,711.6 million a year ago. Basic earnings per share from continuing operations was INR 283.85 compared to INR 221.72 a year ago.
Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.
